80.43
+0.61(+0.76%)
Currency In USD
| Previous Close | 79.82 |
| Open | 80 |
| Day High | 80.73 |
| Day Low | 79.31 |
| 52-Week High | 99.5 |
| 52-Week Low | 30.82 |
| Volume | 167,575 |
| Average Volume | 600,437 |
| Market Cap | 3.04B |
| PE | -14.87 |
| EPS | -5.41 |
| Moving Average 50 Days | 87.83 |
| Moving Average 200 Days | 62.6 |
| Change | 0.61 |
If you invested $1000 in Disc Medicine, Inc. (IRON) since IPO date, it would be worth $780.87 as of December 25, 2025 at a share price of $80.43. Whereas If you bought $1000 worth of Disc Medicine, Inc. (IRON) shares 3 years ago, it would be worth $5,957.78 as of December 25, 2025 at a share price of $80.43.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Disc Medicine Presents Positive Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting
GlobeNewswire Inc.
Dec 06, 2025 1:00 PM GMT
Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response was seen independent of concomitant JAK inhibitor therapy use WATERTOWN, Mass., Dec. 06, 2025 (GLOBE NEWSWIRE)
Disc Medicine Announces Presentation of Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting
GlobeNewswire Inc.
Nov 03, 2025 2:00 PM GMT
WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious h
Disc Medicine Announces Pricing of $250 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire Inc.
Oct 21, 2025 4:14 AM GMT
WATERTOWN, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from s